13F Holdings
中文EN

ANL Adlai Nortye Group Ltd. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1944552 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY52.5%
TTM EPS YoY78.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-103.2%
ROA-51.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets64.2%
Debt / equity0.00x
Current ratio1.41x
Interest coverage-27.23x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$5.00M—$45.73M
R&D expense$44.91M$58.15M$54.49M$42.10M
SG&A expense$9.95M$15.29M$13.04M—
Operating income-$52.93M-$72.55M-$67.27M-$8.65M
Interest expense$1.94M$791,000$433,000$1.34M
Pretax income-$51.87M-$109.23M-$58.79M-$56.68M
Income tax—$643,000——
Net income-$51.87M-$109.23M-$58.79M-$56.68M
EBITDA-$52.42M-$72.09M-$66.66M—
EPS (basic)-0.54-2.52-2.31-2.23
EPS (diluted)-0.54-2.52-2.31-2.23
Weighted avg. shares (diluted)95.78M43.34M25.44M25.44M
Balance sheet
Cash & equivalents$60.90M$91.49M$42.76M$64.13M
Current assets$64.06M$101.19M$66.30M—
PP&E, netmay include right-of-use assets (IFRS)$1.74M$2.65M$3.71M$3.65M
Intangibles$40,000$63,000$89,000—
Total assets$71.27M$130.19M$72.59M—
Current liabilities$45.36M$49.67M$312.65M—
Short-term debt$26.33M$30.36M$4.31M—
Total liabilities$45.78M$55.14M$313.89M—
Shareholders' equity$25.48M$75.05M-$241.29M-$185.43M
Shares outstanding——40.44M—
Cash flow statement
Operating cash flow-$51.82M-$56.65M-$43.22M-$3.03M
Capital expenditure$170,000$200,000$1.25M$1.02M
Free cash flow-$51.99M-$56.85M-$44.47M-$4.05M
Investing cash flow$28.07M-$10.95M$28.38M-$54.86M
Financing cash flow-$6.58M$116.24M-$6.78M$97.20M
Depreciation & amortization$510,000$465,000$609,000—
Stock-based compensation$2.45M$4.33M$6.08M$3.39M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.